BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 26375549)

  • 21. TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis.
    Wang XJ; Li FF; Zhang YJ; Jiang M; Ren WH
    Cancer Biomark; 2020; 29(3):307-315. PubMed ID: 32716348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo.
    Zhou L; Wang Z; Xu X; Wan Y; Qu K; Fan H; Chen Q; Sun X; Liu C
    Oncotarget; 2016 Apr; 7(14):18620-30. PubMed ID: 26921196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma.
    Wang YD; Sun XJ; Yin JJ; Yin M; Wang W; Nie ZQ; Xu J
    Biomed Pharmacother; 2018 Oct; 106():134-141. PubMed ID: 29957463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The RNA-binding protein Sam68 regulates tumor cell viability and hepatic carcinogenesis by inhibiting the transcriptional activity of FOXOs.
    Zhang T; Wan C; Shi W; Xu J; Fan H; Zhang S; Lin Z; Ni R; Zhang X
    J Mol Histol; 2015 Dec; 46(6):485-97. PubMed ID: 26438629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
    Mok WC; Wasser S; Tan T; Lim SG
    World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.
    Ito Y; Matsuura N; Sakon M; Miyoshi E; Noda K; Takeda T; Umeshita K; Nagano H; Nakamori S; Dono K; Tsujimoto M; Nakahara M; Nakao K; Taniguchi N; Monden M
    Hepatology; 1999 Jul; 30(1):90-9. PubMed ID: 10385644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.
    Zhang S; Shi W; Chen Y; Xu Z; Zhu J; Zhang T; Huang W; Ni R; Lu C; Zhang X
    Mol Cell Biochem; 2015 Dec; 410(1-2):1-9. PubMed ID: 26260052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-3663-3p participates in the anti-hepatocellular carcinoma proliferation activity of baicalein by targeting SH3GL1 and negatively regulating EGFR/ERK/NF-κB signaling.
    Tian J; Li J; Bie B; Sun J; Mu Y; Shi M; Zhang S; Kong G; Li Z; Guo Y
    Toxicol Appl Pharmacol; 2021 Jun; 420():115522. PubMed ID: 33838155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-myc downstream regulated gene1/Cap43 overexpression suppresses tumor growth by hepatic cancer cells through cell cycle arrest at the G0/G1 phase.
    Akiba J; Murakami Y; Noda M; Watari K; Ogasawara S; Yoshida T; Kawahara A; Sanada S; Yasumoto M; Yamaguchi R; Kage M; Kuwano M; Ono M; Yano H
    Cancer Lett; 2011 Nov; 310(1):25-34. PubMed ID: 21775055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway.
    Chan KK; Leung CO; Wong CC; Ho DW; Chok KS; Lai CL; Ng IO; Lo RC
    Cancer Lett; 2017 Sep; 403():330-338. PubMed ID: 28688970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition.
    Sun L; Quan H; Xie C; Wang L; Hu Y; Lou L
    PLoS One; 2014; 9(3):e90627. PubMed ID: 24598942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma.
    Cui X; Hu ZP; Li Z; Gao PJ; Zhu JY
    World J Gastroenterol; 2015 Jul; 21(28):8588-604. PubMed ID: 26229401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
    Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
    World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence.
    Xia H; Kong SN; Chen J; Shi M; Sekar K; Seshachalam VP; Rajasekaran M; Goh BKP; Ooi LL; Hui KM
    Cancer Lett; 2016 Dec; 383(1):85-93. PubMed ID: 27693640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VRK1 signaling pathway in the context of the proliferation phenotype in head and neck squamous cell carcinoma.
    Santos CR; Rodríguez-Pinilla M; Vega FM; Rodríguez-Peralto JL; Blanco S; Sevilla A; Valbuena A; Hernández T; van Wijnen AJ; Li F; de Alava E; Sánchez-Céspedes M; Lazo PA
    Mol Cancer Res; 2006 Mar; 4(3):177-85. PubMed ID: 16547155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
    Li X; Yu J; Brock MV; Tao Q; Herman JG; Liang P; Guo M
    Oncotarget; 2015 May; 6(13):11547-60. PubMed ID: 25909168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
    Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.